[ATOS] Atossa Genetics Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.38 Change: -0.02 (-1.43%)
Ext. hours: Change: 0 (0%)

chart ATOS

Refresh chart

Strongest Trends Summary For ATOS

ATOS is in the long-term up 8% in 1 year and down -99% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Fundamental Ratios
Shares Outstanding EPS-2.28 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 18630% Sales Growth - Q/Q283.03% P/E-0.22
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-112.88% ROE-151.51% ROI
Current Ratio3.26 Quick Ratio3.23 Long Term Debt/Equity Debt Ratio0.34
Gross Margin Operating Margin-653.31% Net Profit Margin-656.04% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.29 M Cash From Investing Activities-70 K Cash From Operating Activities-3 M Gross Profit670 K
Net Profit-3.34 M Operating Profit-3.28 M Total Assets13.8 M Total Current Assets11.37 M
Total Current Liabilities3.49 M Total Debt110 K Total Liabilities3.52 M Total Revenue1.87 M
Technical Data
High 52 week9.99 Low 52 week0.92 Last close1.51 Last change-0.36%
RSI54.72 Average true range0.15 Beta0.91 Volume177.7 K
Simple moving average 20 days3.27% Simple moving average 50 days15.81% Simple moving average 200 days-23.94%
Performance Data
Performance Week0.3% Performance Month12.8% Performance Quart19.26% Performance Half-30.84%
Performance Year-62.96% Performance Year-to-date48.49% Volatility daily5.3% Volatility weekly11.84%
Volatility monthly24.27% Volatility yearly84.09% Relative Volume171.06% Average Volume926.47 K
New High New Low


2019-03-28 16:30:00 | Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update

2019-03-27 10:15:00 | _Bull Market Hopping?_

2019-03-26 08:30:00 | Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

2019-03-18 08:30:00 | Atossa Genetics Announces Receipt of $10 Million

2019-03-14 13:01:36 | What Type Of Shareholder Owns Atossa Genetics Inc.’s NASDAQ:ATOS?

2019-03-14 12:53:31 | Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing

2019-03-14 08:30:00 | Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

2019-02-27 06:05:00 | _On Fed's Wings_ Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter

2019-02-07 08:30:00 | Atossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues

2019-02-04 08:30:00 | Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force

2019-01-30 09:15:00 | Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter

2019-01-28 08:00:00 | Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019

2019-01-09 11:58:00 | 4 Healthcare Stocks Looking To Set January Highs

2019-01-09 08:35:48 | Atossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen

2018-12-28 07:20:00 | Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics — What Drives Growth in Today's Competitive Landscape

2018-12-19 08:05:00 | _The Roller Coaster Ride Continues_

2018-12-07 12:07:13 | Edison issues outlook on Atossa Genetics ATOS

2018-12-03 08:00:00 | Atossa Genetics Announces FDA Approval  of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient

2018-11-21 08:05:00 | ''A Spate of Factors'' Vista Partners November 2018 Macro Economic and Investment Newsletter

2018-11-13 16:10:00 | Atossa Genetics Announces Third Quarter 2018 Financial Results And Provides Company Update

2018-10-25 09:10:00 | Report: Exploring Fundamental Drivers Behind Atossa Genetics, Titan International, Olympic Steel, L Brands, Sysco, and TiVo — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-18 16:00:00 | _...Amidst Market Volatility_ Vista Partners' October Macroeconomic & Investment Monthly Newsletter

2018-10-11 08:00:00 | Atossa Genetics Completes Enrollment in Phase 2 Study of Topical Endoxifen in Women with Mammographic Breast Density

2018-09-26 09:05:00 | ''Superfirms' Domination Influences Economic Factors''

2018-09-25 08:20:00 | Report: Developing Opportunities within Crocs, NetApp, Gannett Co., Atossa Genetics, Omega Flex, and Lithia Motors — Future Expectations, Projections Moving into 2018

2018-09-14 09:10:00 | An Interview with Atossa CEO Steven Quay MD, Ph.D. Titled, _What Is Gynecomastia?_

2018-09-13 08:00:00 | Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen

2018-09-12 08:00:00 | Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT

2018-08-23 09:02:00 | ''Robust Economy, Resilient Market''

2018-08-21 09:05:00 | _What Is Intraductal Immuno-oncology & CAR-T Cell Therapy?_

2018-08-13 16:15:00 | Atossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update

2018-08-01 09:05:00 | The Groundwork Forum Podcast Publishes _An Overview of Breast Cancer Treatment Innovator Atossa Genetics_

2018-08-01 08:00:00 | Atossa Genetics Contracts with Additional Manufacturer of Endoxifen

2018-07-31 08:15:00 | Analysis: Positioning to Benefit within Mueller Industries, Eros International, Gannett Co., MarketAxess, Atossa Genetics, and McDonald's — Research Highlights Growth, Revenue, and Consolidated Results

2018-07-30 08:30:00 | Investor Expectations to Drive Momentum within NetApp, eBay, The Boeing, HCP, Atossa Genetics, and Anavex Life Sciences — Discovering Underlying Factors of Influence

2018-07-25 09:05:00 | Vista Partners Publishes July's Macroeconomic & Investment Newsletter

2018-07-18 08:00:00 | Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program

2018-07-13 08:00:00 | Atossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer

2018-06-27 12:55:00 | ''Strong Economy, Trade Wars & Market Volatility''

2018-06-26 08:00:00 | Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density

2018-06-20 08:00:00 | Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men

2018-06-14 08:00:00 | Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board

2018-06-11 21:24:22 | Does Atossa Genetics Inc’s NASDAQ:ATOS -89.06% Earnings Drop Reflect A Longer Term Trend?

2018-05-31 09:05:00 | _The Balancing Act_

2018-05-25 08:00:00 | Atossa Announces $13.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering

2018-05-24 13:32:20 | When Should You Buy Atossa Genetics Inc NASDAQ:ATOS?

2018-05-15 08:00:00 | Atossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men

2018-05-14 16:24:51 | Atossa Genetics To Host Corporate Conference Call Wednesday, May 16, 2018 at 4:30pm EDT

2018-05-14 08:00:00 | Atossa Genetics Announces First Quarter 2018 Financial Results And Provides Company Update

2018-05-11 08:00:00 | Atossa Genetics Supports National Women's Health Week Lead by U.S. Department of Health and Human Services’ Office on Women’s Health